Alpine's Pipeline

We have a diverse pipeline of multi-targeted therapies in development for both autoimmune and inflammatory disease.

Wholly Owned Programs

INFLAMMATORY DISEASES

Povetacicept (ALPN-303)

Dual B Cell Cytokine (BAFF/APRIL) Antagonist

PRECLINICAL

COMPLETED

PHASE 1

PHASE 1b

PHASE 2

NOT STARTED

PHASE 3

NOT STARTED

Systemic Lupus Erythematosus Study

70%
Ruby 2

Commmercial Rights:

Alpine Immune Sciences logo

RUBY-2 study, a placebo-controlled, dose-ranging, randomized phase 2 study in systemic lupus erythematosus (SLE).

PRECLINICAL

COMPLETED

PHASE 1

COMPLETED

PHASE 1b/2a

IN PROGRESS

PHASE 2

NOT STARTED

PHASE 3

NOT STARTED

Glomerulonephritis Basket Study

55%
Ruby 3

Commmercial Rights:

Alpine Immune Sciences logo

RUBY-3 (NCT05732402) – Phase 1b Glomerulonephritis Basket Study

RUBY-3 is a is a multi-ascending dose, multi-cohort open label study that will enroll subjects with proteinuric IgA nephropathy, lupus nephritis or primary membranous nephropathy in small disease- and dose-specific cohorts for up to 48 weeks. Endpoints will include changes in disease-specific autoantibodies as well as proteinuria, eGFR and various definitions of renal response

PRECLINICAL

COMPLETED

PHASE 1

COMPLETED

PHASE 1b

IN PROGRESS

PHASE 2

NOT STARTED

PHASE 3

NOT STARTED

Cytopenia Basket Study

60%
Ruby 4

Commmercial Rights:

Alpine Immune Sciences logo

RUBY-4 (NCT05757570)- Phase 1b Autoimmune Cytopenia Basket Study

RUBY-4 is a parallel-arm, multi-cohort open label study that will enroll patients with immune thrombocytopenia, warm autoimmune hemolytic anemia, or cold agglutinin disease in disease-specific cohorts, using a 2-stage Fleming design for up to 48 weeks. Endpoints will include standard definitions of response, such as durable responses. Changes in anti-platelet or anti-red blood cell autoantibodies will also be followed.

Partnered Programs

Acazicolcept (ALPN-101)

Dual CD28/ICOS Antagonist

PRECLINICAL

COMPLETED

PHASE 1

COMPLETED

PHASE 1b

COMPLETED

PHASE 2

IN PROGRESS

PHASE 3

NOT STARTED

Systemic lupus erythematosus

70%
Synergy logo

Partners:

AbbVie logo

Acazicolcept is a first-in-class dual inhibitor of the CD28 and ICOS T cell costimulatory pathways. The molecule is being developed for treatment of severe inflammatory diseases.

We are currently enrolling Synergy, a phase 2 study of acazicolcept in patients with Systemic Lupus Erythematosus (NCT04835441). This randomized, double-blind, placebo-controlled study was designed to evaluate the safety, tolerability, efficacy, immunogenicity, pharmacokinetics, and pharmacodynamics of acazicolcept.

Learn More

Discovery Collaboration

Immunology

PRECLINICAL

IN PROGRESS

PHASE 1

NOT STARTED

PHASE 1b

NOT STARTED

PHASE 2

NOT STARTED

PHASE 3

NOT STARTED

Undisclosed

15%
Horizon logo

Next Generation TCR T-cell Therapies

PRECLINICAL

IN PROGRESS

PHASE 1

NOT STARTED

PHASE 1b

NOT STARTED

PHASE 2

NOT STARTED

PHASE 3

NOT STARTED

Undisclosed

15%
Adaptimmune logo

For more information on our ongoing clinical trials please refer to the clinical trials portion of our website. For additional information please refer to our corporate filingscorporate presentations, and scientific publications.

Join us in the discovery and development of next-generation immunotherapies.

Current job openingsLearn more about Alpine